SG11202101454PA - Combination therapy using c-c chemokine receptor 4 (ccr4) antagonists and one or more immune checkpoint inhibitors - Google Patents

Combination therapy using c-c chemokine receptor 4 (ccr4) antagonists and one or more immune checkpoint inhibitors

Info

Publication number
SG11202101454PA
SG11202101454PA SG11202101454PA SG11202101454PA SG11202101454PA SG 11202101454P A SG11202101454P A SG 11202101454PA SG 11202101454P A SG11202101454P A SG 11202101454PA SG 11202101454P A SG11202101454P A SG 11202101454PA SG 11202101454P A SG11202101454P A SG 11202101454PA
Authority
SG
Singapore
Prior art keywords
ccr4
antagonists
combination therapy
immune checkpoint
chemokine receptor
Prior art date
Application number
SG11202101454PA
Inventor
Shijie Li
Venkat Reddy Mali
Rajinder Singh
Ju Yang
Penglie Zhang
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of SG11202101454PA publication Critical patent/SG11202101454PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/852—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
SG11202101454PA 2018-08-29 2019-08-28 Combination therapy using c-c chemokine receptor 4 (ccr4) antagonists and one or more immune checkpoint inhibitors SG11202101454PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862724412P 2018-08-29 2018-08-29
US201862771853P 2018-11-27 2018-11-27
PCT/US2019/048461 WO2020047030A1 (en) 2018-08-29 2019-08-28 Combination therapy using c-c chemokine receptor 4 (ccr4) antagonists and one or more immune checkpoint inhibitors

Publications (1)

Publication Number Publication Date
SG11202101454PA true SG11202101454PA (en) 2021-03-30

Family

ID=69639506

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202101454PA SG11202101454PA (en) 2018-08-29 2019-08-28 Combination therapy using c-c chemokine receptor 4 (ccr4) antagonists and one or more immune checkpoint inhibitors

Country Status (14)

Country Link
US (2) US11446289B2 (en)
EP (1) EP3843734A4 (en)
JP (1) JP2021536442A (en)
KR (1) KR20210053306A (en)
CN (1) CN112601526A (en)
AU (1) AU2019327430A1 (en)
BR (1) BR112021002928A2 (en)
CA (1) CA3109498A1 (en)
IL (1) IL280831B1 (en)
MA (1) MA53503A (en)
MX (1) MX2021002302A (en)
SG (1) SG11202101454PA (en)
TW (1) TW202023555A (en)
WO (1) WO2020047030A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX356163B (en) 2011-12-01 2018-05-16 Chemocentryx Inc Substituted anilines as ccr(4) antagonists.
CN112601526A (en) * 2018-08-29 2021-04-02 凯莫森特里克斯股份有限公司 Combination therapy using C-C chemokine receptor 4(CCR4) antagonists and one or more checkpoint inhibitors
KR20230149729A (en) * 2022-04-19 2023-10-27 케모센트릭스, 인크. Ccr4 antagonists

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004010943A2 (en) 2002-07-31 2004-02-05 Smithkline Beecham Corporation Substituted benzanilides as modulators of the ccr5 receptor
JP2007210887A (en) 2004-06-21 2007-08-23 Astellas Pharma Inc Ring-fused bicyclic pyrimidine derivative
US20090182140A1 (en) 2005-12-02 2009-07-16 Mitsubishi Tanabe Pharma Corporation Alicyclic Heterocyclic Compound
EP2240204A1 (en) 2008-02-04 2010-10-20 Medarex, Inc. Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof
WO2011050566A1 (en) 2009-10-26 2011-05-05 中国石油化工股份有限公司 Supported non-metallocene catalyst, preparation method and uses thereof
US8952112B2 (en) 2009-10-26 2015-02-10 China Petroleum & Chemical Corp. Supported nonmetallocene catalyst, preparation and use thereof
CN102753584A (en) 2009-10-28 2012-10-24 埃克森美孚化学专利公司 Catalyst compounds and use thereof
EP2500365B1 (en) 2009-11-13 2020-05-06 China Petroleum & Chemical Corporation Supported non-metallocene catalyst and preparation method and uses thereof
JP5670465B2 (en) 2009-11-13 2015-02-18 中國石油化工股▲分▼有限公司 Supported nonmetallocene catalyst, process for its production and use thereof
JP5937102B2 (en) 2010-12-14 2016-06-22 エレクトロフォレティクス リミテッド Casein kinase 1 delta (CK1 delta) inhibitor
MX356163B (en) * 2011-12-01 2018-05-16 Chemocentryx Inc Substituted anilines as ccr(4) antagonists.
CN105073128A (en) * 2013-04-03 2015-11-18 Ibc药品公司 Combination therapy for inducing immune response to disease
US11236139B2 (en) * 2014-11-05 2022-02-01 The Regents Of The University Of California Combination immunotherapy
SG10201603721TA (en) 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
CN109803651B (en) 2016-06-27 2022-05-31 凯莫森特里克斯股份有限公司 Immunomodulatory compounds
DK3490565T3 (en) * 2016-07-29 2022-07-11 Rapt Therapeutics Inc AZETIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
WO2018101448A1 (en) * 2016-11-30 2018-06-07 Kyowa Hakko Kirin Co., Ltd. Method of treating cancer using anti-ccr4 antibody and anti-pd-1 antibody
CN112601526A (en) * 2018-08-29 2021-04-02 凯莫森特里克斯股份有限公司 Combination therapy using C-C chemokine receptor 4(CCR4) antagonists and one or more checkpoint inhibitors

Also Published As

Publication number Publication date
EP3843734A1 (en) 2021-07-07
BR112021002928A2 (en) 2021-05-11
US20200069673A1 (en) 2020-03-05
IL280831B1 (en) 2024-01-01
EP3843734A4 (en) 2022-05-25
AU2019327430A1 (en) 2021-03-18
US11446289B2 (en) 2022-09-20
JP2021536442A (en) 2021-12-27
IL280831A (en) 2021-04-29
WO2020047030A1 (en) 2020-03-05
MX2021002302A (en) 2021-04-28
CA3109498A1 (en) 2020-03-05
TW202023555A (en) 2020-07-01
US20230097128A1 (en) 2023-03-30
CN112601526A (en) 2021-04-02
MA53503A (en) 2021-07-07
KR20210053306A (en) 2021-05-11

Similar Documents

Publication Publication Date Title
IL280831A (en) Combination therapy using c-c chemokine receptor 4 (ccr4) antagonists and one or more immune checkpoint inhibitors
IL286998A (en) Pyrimidinone derivatives and their use as shp2 antagonists
IL282487A (en) Tyk2 inhibitors and uses thereof
IL286077A (en) Carboxamide-pyrimidine derivatives and their use as shp2 antagonists
ZA201803367B (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
IL271751A (en) Novel t cell receptors and immune therapy using the same
IL280479A (en) Tlr7/8 antagonists and their use
EP3856719C0 (en) Compounds as neuronal histamine receptor-3 antagonists and uses thereof
IL282090A (en) Tyk2 inhibitors and uses thereof
IL273188A (en) Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor
IL283409A (en) Tyk2 inhibitors and uses thereof
ZA202000706B (en) Ballastless track base plate connecting structure and ballastless track having same
IL277144A (en) Adenosine receptor antagonists and uses thereof
EP3712144C0 (en) P2x3 and/or p2x2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof
IL281802A (en) Use of an inhibitor of an ent family transporter in the treatment of cancer and combination thereof with an adenosine receptor antagonist
IL281769A (en) Cd40l antagonist and uses thereof
IL292692A (en) Mrgprx2 antagonists and uses thereof
IL251136A0 (en) Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies
EP4034156A4 (en) Combination therapy with cgrp antagonists
IL282786A (en) Tricyclic janus kinase 1 inhibitors, and compositions and methods thereof
GB201802307D0 (en) CD36 antagonists for use in melanoma treatment
IL288010A (en) Antagonists of the complement system for use in methods of treating paraproteinemic neuropathies
IL281357A (en) Cd73 inhibitors and pharmaceutical uses thereof
IL288085A (en) Expression systems for the alpha 9/alpha 10 nicotinic acetylcholine receptor and methods of use thereof
IL290200A (en) Kv1.3 antagonists for use in the treatment of chronic and acute pain